Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Abstract Background In AFFIRM-AHF, treatment of iron deficiency with intravenous ferric carboxymaltose (FCM) reduced the risk of heart failure (HF) hospitalization and improved quality of life (QoL) vs placebo in patients stabilized following an acute HF (AHF) episode, with no effect on cardiovascul...

Full description

Bibliographic Details
Main Authors: Giuseppe Rosano, Piotr Ponikowski, Cristiana Vitale, Stefan D. Anker, Javed Butler, Vincent Fabien, Gerasimos Filippatos, Bridget-Anne Kirwan, Iain C. Macdougall, Marco Metra, Frank Ruschitzka, Vasuki Kumpeson, Udo-Michael Goehring, Peter van der Meer, Ewa A. Jankowska, the AFFIRM-AHF investigators
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes
Acute heart failure
Iron deficiency
Ferric carboxymaltose
AFFIRM-AHF
Online Access:https://doi.org/10.1186/s12933-023-01943-z

Internet

https://doi.org/10.1186/s12933-023-01943-z

Similar Items